• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

塞来昔布中药物纳米晶体的生成机制:甘露醇纳米晶固体分散体

Mechanism of generation of drug nanocrystals in celecoxib: mannitol nanocrystalline solid dispersion.

作者信息

Bhatt Varun, Shete Ganesh, Bansal Arvind Kumar

机构信息

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Punjab 160062, India.

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Punjab 160062, India.

出版信息

Int J Pharm. 2015 Nov 10;495(1):132-139. doi: 10.1016/j.ijpharm.2015.08.093. Epub 2015 Aug 30.

DOI:10.1016/j.ijpharm.2015.08.093
PMID:26327627
Abstract

Objective of this work was to understand the mechanism of formation of celecoxib nanocrystals in celecoxib: mannitol nanocrystalline solid dispersion (NSD). Solution of celecoxib and mannitol was spray dried in 1:1 (g:g) proportion to obtain NSD, with average crystallite size of 214.07 ± 45.27 nm. Solubility parameters of celecoxib and mannitol were 23.1 MPa(1/2) and 38.5 MPa(1/2), respectively, hinting their immiscibility. Formation of nanocrystals during NanoCrySP proceeds via intermediate amorphous form of the drug. Earlier work from our lab on hesperetin-mannitol system, had underlined the role of plasticization of amorphous drug by excipient in the formation of nanocrystals. However, in present case, mannitol failed to plasticize amorphous celecoxib and Tg of amorphous celecoxib (56.8°C) showed a negligible change (54.8°C) in presence of mannitol. However, DSC data also suggested crystallization inducing potential of mannitol on amorphous celecoxib. Polarized light microscopy provided evidence that, mannitol facilitated heterogeneous nucleation of amorphous celecoxib at their interface. Transmission electron microscopy analysis suggested that, mannitol acted as a physical barrier to crystal growth of celecoxib crystallites. Thus, though mannitol did not plasticize amorphous celecoxib, it aided in nanocrystal generation by heterogeneous nucleation and providing physical barrier to crystal growth.

摘要

本研究的目的是了解塞来昔布

甘露醇纳米晶固体分散体(NSD)中塞来昔布纳米晶体的形成机制。将塞来昔布和甘露醇的溶液按1:1(g:g)的比例进行喷雾干燥以获得NSD,其平均微晶尺寸为214.07±45.27nm。塞来昔布和甘露醇的溶解度参数分别为23.1MPa(1/2)和38.5MPa(1/2),这表明它们互不相溶。纳米晶体在纳米结晶喷雾干燥过程中通过药物的中间无定形形式形成。我们实验室早期关于橙皮素-甘露醇体系的研究强调了辅料对无定形药物的增塑作用在纳米晶体形成中的作用。然而,在目前的情况下,甘露醇未能使无定形塞来昔布增塑,并且在存在甘露醇的情况下,无定形塞来昔布的玻璃化转变温度(Tg)从56.8°C仅出现了可忽略不计的变化(54.8°C)。然而,差示扫描量热法(DSC)数据也表明甘露醇对无定形塞来昔布有结晶诱导潜力。偏光显微镜提供的证据表明,甘露醇在它们的界面处促进了无定形塞来昔布的异相成核。透射电子显微镜分析表明,甘露醇对塞来昔布微晶的晶体生长起到了物理屏障的作用。因此,虽然甘露醇没有使无定形塞来昔布增塑,但它通过异相成核和为晶体生长提供物理屏障来辅助纳米晶体的生成。

相似文献

1
Mechanism of generation of drug nanocrystals in celecoxib: mannitol nanocrystalline solid dispersion.塞来昔布中药物纳米晶体的生成机制:甘露醇纳米晶固体分散体
Int J Pharm. 2015 Nov 10;495(1):132-139. doi: 10.1016/j.ijpharm.2015.08.093. Epub 2015 Aug 30.
2
Oral bioavailability and pharmacodynamic activity of hesperetin nanocrystals generated using a novel bottom-up technology.采用新型自下而上技术制备的橙皮素纳米晶体的口服生物利用度和药效学活性。
Mol Pharm. 2015 Apr 6;12(4):1158-70. doi: 10.1021/mp5008647. Epub 2015 Mar 25.
3
Dual drug nanocrystals loaded microparticles for fixed dose combination of simvastatin and ezetimibe.载有双药纳米晶体的微粒用于辛伐他汀和依折麦布的固定剂量组合。
Pharm Dev Technol. 2020 Jan;25(1):40-53. doi: 10.1080/10837450.2019.1669181. Epub 2019 Oct 24.
4
Anomalous dissolution behavior of celecoxib in PVP/Isomalt solid dispersions prepared using spray drier.使用喷雾干燥机制备的塞来昔布在PVP/异麦芽酮糖醇固体分散体中的异常溶解行为。
Mater Sci Eng C Mater Biol Appl. 2017 Mar 1;72:501-511. doi: 10.1016/j.msec.2016.11.042. Epub 2016 Nov 14.
5
Effect of Mannitol on Nucleation and Crystal Growth of Amorphous Flavonoids: Implications on the Formation of Nanocrystalline Solid Dispersion.甘露醇对无定形黄酮类化合物成核和晶体生长的影响:对纳米晶固体分散体形成的启示
J Pharm Sci. 2015 Nov;104(11):3789-3797. doi: 10.1002/jps.24586. Epub 2015 Jul 16.
6
Improved Release of Celecoxib from High Drug Loading Amorphous Solid Dispersions Formulated with Polyacrylic Acid and Cellulose Derivatives.由聚丙烯酸和纤维素衍生物配制的高载药量非晶态固体分散体中塞来昔布的释放改善
Mol Pharm. 2016 Mar 7;13(3):873-84. doi: 10.1021/acs.molpharmaceut.5b00798. Epub 2016 Feb 2.
7
Impact of surfactants on the crystal growth of amorphous celecoxib.表面活性剂对无定形塞来昔布晶体生长的影响。
Int J Pharm. 2014 Jan 30;461(1-2):251-7. doi: 10.1016/j.ijpharm.2013.11.057. Epub 2013 Dec 9.
8
Barrier coated drug layered particles for enhanced performance of amorphous solid dispersion dosage form.包衣药物层颗粒提高无定形固体分散体剂型的性能。
J Pharm Sci. 2012 Jan;101(1):342-53. doi: 10.1002/jps.22743. Epub 2011 Sep 20.
9
An investigation into the role of polymeric carriers on crystal growth within amorphous solid dispersion systems.聚合物载体在无定形固体分散体系中晶体生长作用的研究。
Mol Pharm. 2015 Apr 6;12(4):1180-92. doi: 10.1021/mp500702s. Epub 2015 Mar 6.
10
Dissolution Performance of High Drug Loading Celecoxib Amorphous Solid Dispersions Formulated with Polymer Combinations.采用聚合物组合制备的高载药量塞来昔布无定形固体分散体的溶出性能
Pharm Res. 2016 Mar;33(3):739-50. doi: 10.1007/s11095-015-1823-y. Epub 2015 Nov 12.

引用本文的文献

1
Study on the regulation mechanism of effective glass transition temperature on the crystallization of crystalline solid dispersion.研究有效玻璃化转变温度对结晶固体分散体结晶的调控机制。
Drug Deliv Transl Res. 2023 Oct;13(10):2677-2689. doi: 10.1007/s13346-023-01348-1. Epub 2023 Apr 25.
2
Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation.具有增强溶解度、溶解速率和口服生物利用度的塞来昔布纳米制剂:体外/体内评价的实验方法
Pharmaceutics. 2023 Jan 20;15(2):363. doi: 10.3390/pharmaceutics15020363.
3
Celecoxib-Loaded Solid Lipid Nanoparticles for Colon Delivery: Formulation Optimization and In Vitro Assessment of Anti-Cancer Activity.
用于结肠给药的塞来昔布固体脂质纳米粒:制剂优化及抗癌活性的体外评估
Pharmaceutics. 2022 Jan 5;14(1):131. doi: 10.3390/pharmaceutics14010131.
4
Microemulsion systems: from the design and architecture to the building of a new delivery system for multiple-route drug delivery.微乳液体系:从设计和结构到建立多途径药物传递的新给药系统。
Drug Deliv Transl Res. 2021 Oct;11(5):2108-2133. doi: 10.1007/s13346-020-00872-8. Epub 2020 Nov 8.
5
Comparison of Downstream Processing of Nanocrystalline Solid Dispersion and Nanosuspension of Diclofenac Acid to Develop Solid Oral Dosage Form.双氯芬酸纳米晶固体分散体和纳米混悬液的下游处理以开发固体口服剂型的比较
Pharmaceutics. 2020 Oct 23;12(11):1015. doi: 10.3390/pharmaceutics12111015.
6
Evaluation of Different Techniques for Size Determination of Drug Nanocrystals: A Case Study of Celecoxib Nanocrystalline Solid Dispersion.不同技术用于药物纳米晶体粒径测定的评估:以塞来昔布纳米晶固体分散体为例
Pharmaceutics. 2019 Oct 7;11(10):516. doi: 10.3390/pharmaceutics11100516.
7
Nanocrystalization: An Emerging Technology to Enhance the Bioavailability of Poorly Soluble Drugs.纳米晶化:一种提高难溶性药物生物利用度的新兴技术。
Pharm Nanotechnol. 2019;7(4):259-278. doi: 10.2174/2211738507666190405182524.
8
NanoCrySP technology for generation of drug nanocrystals: translational aspects and business potential.纳米结晶喷雾干燥技术制备药物纳米结晶:转化方面和商业潜力。
Drug Deliv Transl Res. 2016 Aug;6(4):392-8. doi: 10.1007/s13346-016-0286-y.